Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $72.71. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | VEA | |
|---|---|---|
Market Cap | $1.78B | — |
Sector | Health | — |
52-Week High | $6.79 | $72.89 |
52-Week Low | $2.84 | $58.19 |
Enterprise Value | $1.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
VEA trades at $72.89, up 1.07% today, with a bullish technical outlook supported by moving averages. The ETF focuses on developed markets outside the U.S., offering low-cost diversification. Recent news highlights mixed institutional activity, with some firms increasing stakes while others reduce holdings, reflecting varied sentiment toward international equity exposure.
The outlook for VEA is supported by its low expense ratio and diversification benefits, but risks include currency fluctuations and geopolitical tensions in developed markets. Analyst comparisons favor VEA for cost efficiency, though performance relative to U.S. indices remains a key consideration for investors seeking global allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
